Assessment Of Fructosamine Versus Hba1c For Glycaemic Monitoring In Pregnancy-Associated Hyperglycaemia: A Cross-Sectional Study
DOI:
https://doi.org/10.64252/mhqxgn95Keywords:
Fructosamine, Hyperglycaemia, Pregnancy, Gestational Diabetes, Glycaemic Monitoring, HbA1c, Maternal Outcomes, BiomarkerAbstract
Background: Fructosamine reflects short-term glycaemic control and may serve as a useful alternative to HbA1c in pregnancy, where rapid glycaemic fluctuations occur. This study evaluates fructosamine's utility in monitoring hyperglycaemia during pregnancy and its correlation with maternal and fetal outcomes.
Objectives: To assess the correlation between fructosamine and HbA1c, fasting blood sugar (FBS), postprandial blood sugar (PPBS), and to evaluate its association with feto-maternal outcomes.
Methods: In this prospective study (May 2023 – Nov 2024), pregnant women in their second trimester were screened using the glucose challenge test (GCT). Based on GCT results, participants were grouped into hyperglycaemic cases and normoglycemic controls. All underwent evaluation of fructosamine, HbA1c, FBS, and PPBS. Correlations between markers and clinical outcomes were analysed.
Results: Fructosamine levels were significantly higher in hyperglycaemic cases compared to controls and showed strong positive correlation with HbA1c, FBS, and PPBS. Elevated fructosamine levels were also associated with increased risk of adverse maternal and neonatal outcomes.
Conclusion: Fructosamine is a reliable marker of short-term glycaemic control in pregnancy and correlates well with conventional markers. Its association with adverse outcomes supports its role as an alternative to HbA1c, particularly where HbA1c may be limited. Routine use of fructosamine could improve monitoring and management of gestational hyperglycaemia.
